GC
SUPN icon

Guidance Capital’s Supernus Pharmaceuticals SUPN Stock Holding History

Guidance Capital’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$664K Buy
13,763
+319
+2% +$15.3K 0.14% 147
2026
Q1 		$661K Buy
+13,444
New +$685K 0.15% 142

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Guidance Capital's SUPN Position: Q2 2026 in Review

Guidance Capital increased its Supernus Pharmaceuticals (SUPN) stake by 2.4% in Q2 2026, buying an estimated $15.3K and bringing the position to 13,763 shares worth $664K. The position accounts for 0.14% of the portfolio, ranked #147.

Guidance Capital first reported a position in SUPN in Q1 2026 and has held it in 2 quarters since. 335 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Guidance Capital held 13,763 shares of Supernus Pharmaceuticals worth $664K as of Q2 2026.
  • Guidance Capital bought 319 Supernus Pharmaceuticals shares in Q2 2026, an estimated $15.3K.
  • Supernus Pharmaceuticals made up 0.14% of Guidance Capital's portfolio in Q2 2026, its #147 holding.
  • Guidance Capital first reported a position in Supernus Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 335 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Guidance Capital's 13F filing for Q2 2026, filed 20 Jul 2026.